サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1771594

米国の高分子創薬アウトソーシング市場規模、シェア、動向分析レポート：ワークフロー別、サービス別、治療薬分野別、最終用途別、セグメント予測、2025年～2033年

U.S. Large Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow (Target Identification & Screening), By Service, By Therapeutics Area (Ophthalmology, Hematology), By End-use, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.50円
米国の高分子創薬アウトソーシング市場規模、シェア、動向分析レポート：ワークフロー別、サービス別、治療薬分野別、最終用途別、セグメント予測、2025年～2033年
出版日: 2025年06月16日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向：

米国の高分子創薬アウトソーシング市場規模は2024年に9億6,860万米ドルと推計され、2025年から2033年にかけてCAGR 9.20％で成長すると予測されます。

同市場は、革新的な生物製剤への製薬業界のシフトが加速し、生物製剤のパイプラインが拡大していることを背景に、力強い成長を遂げています。また、モノクローナル抗体、二重特異性抗体、融合蛋白質、抗体薬物複合体（ADC）などの高分子は、がん、自己免疫疾患、慢性疾患など様々な疾患の治療薬として、引き続き需要が高まっています。

米国では、製薬企業やバイオテクノロジー企業が、創薬プロセスの迅速化、コスト削減、専門技術へのアクセスを得るために、CRO（医薬品開発業務受託機関）を利用するケースが増えています。これらのアウトソーシング・パートナーシップは、リード化合物の同定、候補化合物の最適化、生物学的サービス、前臨床開発など様々なサービスを提供しており、統合されたプラットフォームベースのアウトソーシング・モデルへの移行が進んでいます。さらに、生物製剤、特に融合タンパク質や人工抗体などの次世代フォーマットに対する需要の高まりから、企業はサイクルタイムの短縮と複雑性の管理のために探索業務をアウトソーシングするようになっています。

精密スクリーニング、標的生物学、in vitro機能解析に重点を置いたアウトソーシングは、分子の最適化と早期の製造可能性評価を強化します。希少疾患や個別化免疫療法といったニッチな治療領域の台頭により、高度にカスタマイズされた創薬ソリューションの必要性がさらに高まっています。また、単一のパートナーネットワークを通じて探索、前臨床、早期開発活動を統合するアウトソーシングモデルが、推定期間を通じて市場を牽引すると予想されます。米国では、AIを活用した標的探索、マイクロ流体ベースのスクリーニング、クライオ電子顕微鏡、クラウドネイティブプラットフォームなどの技術的進歩に焦点が当てられており、広範な分子創薬のアウトソーシングは、多様な開発プログラムにわたる生物学的製薬の創薬の戦略的実現要因になりつつあり、市場の成長をさらに後押ししています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の高分子創薬アウトソーシング市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • テクノロジー情勢
  • 価格モデル分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • SWOT分析によるPESTEL

第4章 米国の高分子創薬アウトソーシング市場：ワークフローの推定・動向分析

  • 米国の高分子創薬アウトソーシング市場（ワークフロー別）：セグメントダッシュボード
  • 米国の高分子創薬アウトソーシング市場、ワークフロー別：変動分析
  • ワークフロー別、2021～2033年
  • ターゲットの特定とスクリーニング
  • ターゲット検証と機能情報科学
  • リード特定と候補者最適化
  • 前臨床開発
  • その他

第5章 米国の高分子創薬アウトソーシング市場：サービス推定・動向分析

  • 米国の高分子創薬アウトソーシング市場（サービス別）：セグメントダッシュボード
  • 米国の高分子創薬アウトソーシング市場、サービス別：変動分析
  • サービス別、2021～2033年
  • 化学サービス
  • 生物学サービス

第6章 米国の高分子創薬アウトソーシング市場：治療薬分野の推定・動向分析

  • 米国の高分子創薬アウトソーシング市場（治療薬分野別）：セグメントダッシュボード
  • 米国の高分子創薬アウトソーシング市場、治療薬分野別：変動分析
  • 治療薬分野別、2021～2033年
  • 呼吸器系
  • 痛みと麻酔
  • 腫瘍学
  • 眼科
  • 血液学
  • 心血管系
  • 内分泌
  • 胃腸
  • 免疫調節
  • 抗感染性
  • 中枢神経系
  • 皮膚科
  • 泌尿生殖器系

第7章 米国の高分子創薬アウトソーシング市場：最終用途の推定・動向分析

  • 米国の高分子創薬アウトソーシング市場（最終用途別）：セグメントダッシュボード
  • 米国の高分子創薬アウトソーシング市場、最終用途別：変動分析
  • 用途別、2021～2033年
  • 製薬・バイオテクノロジー企業
  • 学術機関

第8章 競合情勢

  • 市場参入企業の分類
    • マーケットリーダー
    • 新興企業
  • 企業市場シェア/評価分析、2024年
  • 企業プロファイル
    • Charles River Laboratories International, Inc.
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific, Inc.
    • GenScript Biotech Corporation
    • Syngene International Limited
    • Dalton Pharma Services
    • Eurofins Scientific SE
    • TCG Lifesciences Pvt Ltd.
    • Evotec SE
    • WuXi AppTec
    • Jubilant Biosys Limited
    • Pharmaron Beijing Co., Ltd.

第9章 主な推奨事項

図表

List of Tables

  • Table 1. List of Tables
  • Table 2. List of Secondary Sources
  • Table 3. List of Abbreviations
  • Table 4. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 5. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 7. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Large Molecule Drug Discovery Outsourcing Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Large Molecule Drug Discovery Outsourcing Market: Workflow outlook and key takeaways
  • Fig. 20 U.S. Large Molecule Drug Discovery Outsourcing Market: Workflow movement analysis
  • Fig. 21 Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Large Molecule Drug Discovery Outsourcing Market: Service outlook and key takeaways
  • Fig. 27 U.S. Large Molecule Drug Discovery Outsourcing Market: Service movement analysis
  • Fig. 28 Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Large Molecule Drug Discovery Outsourcing Market: Therapeutics Area outlook and key takeaways
  • Fig. 31 U.S. Large Molecule Drug Discovery Outsourcing Market: Therapeutics Area movement analysis
  • Fig. 32 Respiratory system Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. Large Molecule Drug Discovery Outsourcing Market: End Use outlook and key takeaways
  • Fig. 46 U.S. Large Molecule Drug Discovery Outsourcing Market: End Use movement analysis
  • Fig. 47 Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key company categorization
  • Fig. 50 Service heat map analysis
  • Fig. 51 Strategic framework
目次
Product Code: GVR-4-68040-624-7

Market Size & Trends:

The U.S. large molecule drug discovery outsourcing market size was estimated at USD 968.60 million in 2024 and is projected to grow at a CAGR of 9.20% from 2025 to 2033. The market is experiencing robust growth, driven by the accelerating shift in the pharmaceutical industry towards innovative biologics and expanding pipeline biologics. Besides, large molecules, including monoclonal antibodies, bispecific, fusion proteins, and antibody-drug conjugates (ADCs), continue to witness rising demand to treat various diseases, including cancer, autoimmune disorders, and chronic conditions.

In the U.S., pharmaceutical and biotechnology companies are increasingly turning to contract research organizations (CROs) to accelerate the discovery process, lower costs, and gain access to specialized technologies. These outsourcing partnerships provide various services, including lead identification, candidate optimization, biology services, and preclinical development, with a shift toward integrated, platform-based outsourcing models. Moreover, rising demand for biologics, particularly next-generation formats such as fusion proteins and engineered antibodies, has led companies to outsource discovery tasks to reduce cycle times and manage complexity.

Outsourcing the company's focus on precision screening, target biology, and in vitro functional analysis enhances molecular optimization and early manufacturability assessments. The rise of niche therapeutic areas, such as rare diseases and personalized immunotherapies, further increases the need for highly customized discovery solutions. Besides, integrated outsourcing models that combine discovery, preclinical, and early development activities through a single partner network are expected to drive the market over the estimated period. With a focus on technological advancements in the U.S., including AI-driven target discovery, microfluidics-based screening, cryo-electron microscopy, and cloud-native platforms, outsourcing for extensive molecule drug discovery is becoming a strategic enabler of biologic drug discovery across diverse development programs, which further supports the market growth.

U.S. Large Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. large molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, and end-use:

  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Target Identification & Screening
  • Target Validation & Functional Informatics
  • Lead Identification & Candidate Optimization
  • Preclinical Development
  • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemistry Services
  • Biology Services
  • Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Respiratory system
  • Pain and Anesthesia
  • Oncology
  • Ophthalmology
  • Hematology
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology companies
  • Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Large Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Force Analysis
    • 3.5.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Large Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
  • 4.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
  • 4.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021-2033 (USD Million)
  • 4.4. Target Identification & Screening
    • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Target Validation & Functional Informatics
    • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Lead Identification & Candidate Optimization
    • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Preclinical Development
    • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Large Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

  • 5.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By Service: Segment Dashboard
  • 5.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By Service: Movement Analysis
  • 5.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021-2033 (USD Million)
  • 5.4. Chemistry Services
    • 5.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biology Services
    • 5.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Large Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 6.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
  • 6.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
  • 6.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021-2033 (USD Million)
  • 6.4. Respiratory system
    • 6.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pain and Anesthesia
    • 6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Ophthalmology
    • 6.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Hematology
    • 6.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Cardiovascular
    • 6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Endocrine
    • 6.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Gastrointestinal
    • 6.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Immunomodulation
    • 6.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.13. Anti-infective
    • 6.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.14. Central Nervous System
    • 6.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.15. Dermatology
    • 6.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.16. Genitourinary System
    • 6.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Large Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

  • 7.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
  • 7.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By End Use: Movement Analysis
  • 7.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021-2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology companies
    • 7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Academic Institutes
    • 7.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Charles River Laboratories International, Inc.
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Laboratory Corporation of America Holdings
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Thermo Fisher Scientific, Inc.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. GenScript Biotech Corporation
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Syngene International Limited
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Dalton Pharma Services
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Eurofins Scientific SE
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. TCG Lifesciences Pvt Ltd.
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Evotec SE
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. WuXi AppTec
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Jubilant Biosys Limited
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Pharmaron Beijing Co., Ltd.
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives

Chapter 9 Key Recommendations